<?xml version="1.0"?>
<!DOCTYPE TimeML SYSTEM "TimeML.dtd">
<TimeML>
Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) has received a consensus rating of “Buy” from the five research firms that are presently  covering the firm. One research analyst  has rated the stock with a sell rating and four have given a buy rating to  the company. The average <TIMEX3 tid="t2" type="DURATION" value="P1Y">1-year</TIMEX3> target price among brokers that have issued a report on the stock in <TIMEX3 tid="t1" type="DATE" value="2016">the last year</TIMEX3> is $17.33. 
 
Several analysts have issued reports on TRHC shares. Robert W. Baird started coverage on Tabula Rasa Healthcare in a research note on <TIMEX3 tid="t5" type="DATE" value="2016-10-24">Monday, October 24th</TIMEX3>. They issued an “outperform” rating and a $17.00 target price for the company. Wells Fargo & Company started coverage on Tabula Rasa Healthcare in a research note on <TIMEX3 tid="t9" type="DATE" value="2016-10-24">Monday, October 24th</TIMEX3>. They issued an “outperform” rating for the company. Zacks Investment Research raised Tabula Rasa Healthcare from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on <TIMEX3 tid="t13" type="DATE" value="2017-12-27">Tuesday, December 27th</TIMEX3>. Stifel Nicolaus began coverage on Tabula Rasa Healthcare in a research note on <TIMEX3 tid="t17" type="DATE" value="2016-10-24">Monday, October 24th</TIMEX3>. They issued a “buy” rating and a $17.00 target price for the company. Finally, Piper Jaffray Companies began coverage on Tabula Rasa Healthcare in a research note on <TIMEX3 tid="t21" type="DATE" value="2016-10-24">Monday, October 24th</TIMEX3>. They set an “overweight” rating and a $18.00 price objective for the company. 
 
Hedge funds have <TIMEX3 tid="t23" type="DATE" value="PAST_REF">recently</TIMEX3> added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new stake in  Tabula Rasa Healthcare during <TIMEX3 tid="t24" type="DATE" value="2016-Q4">the fourth quarter</TIMEX3> worth $875,000.  Sio Capital Management LLC acquired a new position in shares of  Tabula Rasa Healthcare during <TIMEX3 tid="t25" type="DATE" value="2016-Q3">the third quarter</TIMEX3> worth approximately $7,303,000.  Laurion Capital Management LP acquired a new position in shares of  Tabula Rasa Healthcare during <TIMEX3 tid="t26" type="DATE" value="2016-Q3">the third quarter</TIMEX3> worth approximately $430,000.  Emerald Acquisition Ltd. acquired a new position in shares of  Tabula Rasa Healthcare during <TIMEX3 tid="t27" type="DATE" value="2016-Q3">the third quarter</TIMEX3> worth approximately $592,000.  Finally, Boston Partners acquired a new position in shares of  Tabula Rasa Healthcare during <TIMEX3 tid="t28" type="DATE" value="2016-Q3">the third quarter</TIMEX3> worth approximately $2,682,000. 23.48% of the stock is owned by hedge funds and other institutional investors. 
 
TRADEMARK VIOLATION WARNING: This article was first  published by [[site]] and is owned by of [[site]]. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this article can be read at [[permalink]]. 
 
Shares of Tabula Rasa Healthcare ( NASDAQ:TRHC ) opened at 14.27 on <TIMEX3 tid="t29" type="DATE" value="2017-01-26">Thursday</TIMEX3>. The stock has a <TIMEX3 tid="t32" type="DURATION" value="P50D">50 day</TIMEX3> moving average of $14.17 and a <TIMEX3 tid="t33" type="DURATION" value="P200D">200 day</TIMEX3> moving average of $13.20. Tabula Rasa Healthcare has a <TIMEX3 tid="t34" type="DURATION" value="P1Y">1-year</TIMEX3> low of $10.39 and a <TIMEX3 tid="t35" type="DURATION" value="P1Y">1-year</TIMEX3> high of $16.17. The company has a market cap of $229.76 million and a price-to-earnings ratio of 55.10. 
 
Tabula Rasa Healthcare (NASDAQ:TRHC) last issued its earnings results on <TIMEX3 tid="t38" type="DATE" value="2016-11-09">Wednesday, November 9th</TIMEX3>. The company reported $0.06 earnings per share (EPS) for <TIMEX3 tid="t40" type="DATE" value="2016-Q4">the quarter</TIMEX3>, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.03. The firm earned $24.20 million during <TIMEX3 tid="t41" type="DATE" value="2016-Q4">the quarter</TIMEX3>. The firm’s revenue for <TIMEX3 tid="t42" type="DATE" value="2016-Q4">the quarter</TIMEX3> was up 34.4% on a year-over-year basis.  Analysts predict that  Tabula Rasa Healthcare will post $0.23 EPS for <TIMEX3 tid="t46" type="DATE" value="2017">the current year</TIMEX3>. 
 
Tabula Rasa Healthcare Company Profile 
 
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
</TimeML>
